Jeff Cole's appointment as COO of Cadrenal Therapeutics is a significant development for the company, especially as it approaches the critical Phase 3 trial of tecarfarin. Cole's extensive experience in pharmaceutical operations and commercialization is likely to positively impact the company's strategy and execution, potentially leading to a positive market perception and investor confidence. This strategic move could be seen as a strengthening of the leadership team in preparation for the next stages of tecarfarin's development and commercialization, which may positively influence the company's stock price in the short term.